Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes

British Journal of Pharmacology

Volumn 171, Issue 24, 2014, Pages 5624-5635

  Maximov, Philipp Y ^a   McDaniel, Russell E ^a   Fernandes, Daphne J ^a   Korostyshevskiy, Valeriy R ^a   Bhatta, Puspanjali ^a   Mürdter, Thomas E ^b   Flockhart, David A ^c   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CYTOCHROME P450 2D6; ENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; N-DESMETHYLTAMOXIFEN;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; GENOTYPE; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOBLOTTING; IN VITRO STUDY; PREMENOPAUSE; REAL TIME POLYMERASE CHAIN REACTION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETIC VARIABILITY; GENETICS; MCF 7 CELL LINE; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IN VITRO TECHNIQUES; MCF-7 CELLS; PREMENOPAUSE; TAMOXIFEN;

EID: 84919343628     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12864     Document Type: Article

References (40)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Allen KE, Clark ER, Jordan VC, (1980). Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 71: 83-91.
4. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-784.
5. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381: 805-816.
6. Dehal SS, Kupfer D, (1997). CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57: 3402-3406.
7. Desta Z, Ward BA, Soukhova NV, Flockhart DA, (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310: 1062-1075.
8. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. (2010). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28: 509-518.
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
10. Furr BJ, Jordan VC, (1984). The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205.
11. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312-9318.
12. Goetz MP, Suman VA, Reid JR, Northfelt DW, Mahr MA, Dockter T, et al. (2013) A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). Abstract PD3-4. San Antonio Breast Cancer Symposium: San Antonio, TX.
13. Gong IY, Teft WA, Ly J, Chen YH, Alicke B, Kim RB, et al. (2013). Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res Treat 139: 61-69.
14. Hawse JR, Subramaniam M, Cicek M, Wu X, Gingery A, Grygo SB, et al. (2013). Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS ONE 8: e54613.
15. Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, et al. (2011). Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29: 3232-3239.
16. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. (2004). Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85: 151-159.
17. Jordan VC, (1984). Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245-276.
18. Jordan VC, Brodie AM, (2007). Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72: 7-25.
19. Jordan VC, Collins MM, Rowsby L, Prestwich G, (1977). A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305-316.
20. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC, (1991). Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488-1491.
21. Langan-Fahey SM, Tormey DC, Jordan VC, (1990). Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26: 883-888.
22. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, et al. (2006). Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318: 503-512.
23. Maximov PY, Fernandes DJ, McDaniel RE, Myers CB, Curpan RF, Jordan VC, (2014). Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells. J Med Chem 57: 4569-4583.
24. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. (2011). Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89: 708-717.
25. Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, Katzenellenbogen BS, (1995). Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci 761: 148-163.
26. Obiorah IE, Sengupta S, Curpan R, Jordan VC, (2014). Defining the conformation of the estrogen receptor complex that controls estrogen induced apoptosis in breast cancer. Mol Pharmacol 85: 789-799.
27. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al. (1995). Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746-750.
28. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
29. Pink JJ, Jordan VC, (1996). Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330.
30. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, et al. (2014). CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95: 216-227.
31. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. (2012). CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104: 452-460.
32. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. (2012). CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 Trial. J Natl Cancer Inst 104: 441-451.
33. Robinson SP, Langan-Fahey SM, Jordan VC, (1989). Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol 25: 1769-1776.
34. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC, (1991). Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19: 36-43.
35. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302: 1429-1436.
36. Soule HD, McGrath CM, (1980). Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett 10: 177-189.
37. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764.
38. Wardell SE, Nelson ER, Chao CA, McDonnell DP, (2013). Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 19: 2420-2431.
39. Weinstein Y, (1978). Impairment of the hypothalamo-pituitary-ovarian axis of the athymic 'nude' mouse. Mech Ageing Dev 8: 63-68.
40. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC, (2009). The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69: 1722-1727.